Abelacimab: A leap forward in anticoagulation with FXI and FXIa Inhibition
Direct Oral Anticoagulants (DOACs) have revolutionized the treatment of thromboembolic disorders, offering targeted, effective, and safer alternatives to traditional anticoagulants like heparins and vitamin K antagonists (VKAs). Despite their benefits, DOACs have drawbacks, including an increased ri...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier
2024-01-01
|
| Seri Bilgileri: | Current Research in Pharmacology and Drug Discovery |
| Konular: | |
| Online Erişim: | http://www.sciencedirect.com/science/article/pii/S2590257124000063 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|